While debates about deepfakes and chatbot safety grab headlines, a quieter but potentially more consequential wave of AI regulation is emerging in healthcare. At least 34 state bills introduced in 2026 specifically target AI in healthcare settings — from insurance claim processing to clinical decision support to diagnostic imaging. The stakes are enormous: healthcare AI is projected to be a $45 billion market by 2028, and the regulatory decisions being made now will determine how that technology is deployed and governed.
The hottest issue is AI-driven insurance claim denials. Investigative reporting in 2025 revealed that major health insurers were using AI algorithms to automatically deny claims at rates far exceeding human reviewers — in some cases rejecting claims in under two seconds without meaningful clinical review. The backlash was immediate. Washington State's SB 5395, the "Fair Insurance AI Act," would require insurers to disclose when AI is used in claim decisions, mandate human review of all AI-generated denials, and prohibit the use of AI models trained primarily on cost-reduction metrics.
Alabama's SB 63 and Georgia's SB 444 take similar approaches but go further, requiring insurers to submit their AI models for state regulatory review before deployment. These bills have been fiercely opposed by the insurance industry — UnitedHealth Group alone spent $1.8 million lobbying on healthcare AI bills in Q1 2026. See our company profiles for detailed lobbying breakdowns. The American Health Insurance Plans (AHIP) trade group argues that AI actually improves claim processing accuracy and speed, and that heavy-handed regulation would increase costs for consumers.
Beyond insurance, states are grappling with AI in clinical settings. The FDA has cleared over 700 AI-enabled medical devices, from radiology tools to cardiac monitors, but state-level regulation of how these tools are used in practice remains sparse. California's AB 1721 would require healthcare providers to inform patients when AI tools are used in their diagnosis or treatment recommendations. New York's S. 4892 would mandate regular audits of clinical AI systems for racial and socioeconomic bias.
The lobbying numbers tell their own story. Healthcare AI companies and industry groups spent $4.2 million on state-level lobbying in Q1 2026 alone — a 180% increase over the same quarter in 2025. The biggest spenders include health insurers (UnitedHealth, Anthem, Cigna), AI health tech companies (Tempus, PathAI), and pharmaceutical giants deploying AI in drug discovery (Pfizer, Roche). Track lobbying trends on our Follow the Money page.
What makes healthcare AI regulation uniquely challenging is the intersection of multiple regulatory regimes. The FDA regulates medical devices, CMS sets rules for Medicare and Medicaid, state insurance commissioners oversee insurers, and state medical boards govern clinical practice. No single agency has comprehensive authority over healthcare AI, creating gaps that state legislatures are now trying to fill. The result is likely to be another patchwork — unless federal preemption, which the industry is pushing hard for, takes hold first.